Improvement in the definition of anti-HLA antibody profile in highly sensitized patients

The definition of anti-HLA antibody profile in highly sensitized patients on a waiting list is crucial when virtual crossmatch is used in organ allocation systems, but also when used to identify the true deleterious anti-HLA antibodies. Here we propose different levels of risk based on the results of anti-HLA antibody testing in neat serum (N) and after sera dilution (DIL) and C1q test in 18 highly sensitized patients. This group was heterogeneous in terms of anti-HLA antibody titers and their ability to fix complement. After dilution, 15 out of 18 patients (83.3%) showed a reduction of positive bead counts whereas 4 patients showed a prozone effect and complement fixation was demonstrated. The high dilution of sera and ascertaining the complement fixation allow the accurate definition of risk anti-HLA antibody profiles in highly sensitized patients, as demonstrated in 5 of the sensitized patients who were transplanted.

[1]  M. Berth.  Complement Interference Is Not the Same as a Prozone Phenomenon , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  J. Taupin,et al.  Assessing HLA Antibody Strength: Have We Thought About Everything? , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  J. Friedewald,et al.  Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  S. Daburon,et al.  Deciphering Complement Interference in Anti–Human Leukocyte Antigen Antibody Detection With Flow Beads Assays , 2014, Transplantation.

[5]  J. Moreau,et al.  The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. , 2013, Transplant immunology.

[6]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[7]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[8]  C. Napoli,et al.  Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. , 2011, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[9]  R. Holdsworth,et al.  Solid phase HLA antibody detection technology--challenges in interpretation. , 2010, Tissue antigens.

[10]  S. Kleinman,et al.  Identification of specificities of antibodies against human leukocyte antigens in blood donors , 2010, Transfusion.

[11]  T. Mohanakumar,et al.  Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. , 2010, Human immunology.

[12]  J. Friedewald,et al.  Perception Versus Reality?: Virtual Crossmatch—How to Overcome Some of the Technical and Logistic Limitations , 2009 .

[13]  R. Bray,et al.  Strategies for human leukocyte antigen antibody detection. , 2009, Current opinion in organ transplantation.

[14]  A. Jackson.  The Virtual Crossmatch: An Essential Tool for Transplanting Sensitized Patients. , 2014, Clinical transplants.